Eccogene is a clinical stage biopharmaceutical company developing small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. The company focuses on safer and more effective oral therapies that target obesity and its comorbidities.

Eccogene

Eccogene | 609 followers on LinkedIn. Unlocking the full potential of GLP-1-based therapy  | Eccogene is focused on building a pipeline of best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions with the goal of improving care and expanding access to cost effective medicines for millions of patients worldwide. Since our inception, our team has been dedicated to discovering safer and more effective oral therapies that may be used alone or synergistically with a GLP-1 receptor agonist to treat conditions beyond obesity.

Among our core strengths is our team -- comprised of individuals with world-class expertise in translational research and small molecule discovery -- as well as our deep understanding of diabetes, weight loss and cardiometabolic disease pathways.

Advancing life sciences innovations

Tim Xiao, CFA, FRM

Co-founder and CEO at Eccogene Inc

Jingye Zhou

Chief Financial Officer at Eccogene

Glenn Reicin

Senior Director of Pharmaceutical Sciences, Formulation Development at Karyopharm Therapeutics

Wen Chen

That’s a wrap on ObesityWeek 2024! Thank you to The Obesity Society for organizing a fantastic forum where researchers from around the world came together to showcase the latest in obesity science. #OW2024

This afternoon, two posters featuring Phase 1 data on ECC5004/AZD5004 will be presented at The Obesity Society 's #OW2024 . These findings support the rapid clinical advancement of this candidate, with the first patients in the Phase 2b trials for obesity and type 2 diabetes already dosed.

Today marks the beginning of ObesityWeek 2024! The Eccogene team has arrived in San Antonio and is thrilled to join this premier international conference for obesity researchers and clinicians. Tomorrow, Phase 1 results with our oral small molecule GLP-1 receptor agonist, ECC5004/AZD5004, will be unveiled for the first time in a poster session at 2:30 PM CT. For those at the meeting, we hope to see you there. The Obesity Society #OW2024

We are pleased to announce that our partner AstraZeneca dosed the first patients in the two Phase 2 trials of ECC5004/AZD5004 for the treatment of obesity and type diabetes. For more information, click here: https://lnkd.in/d4SW3RmM

We are pleased to welcome Glenn Reicin as Chief Financial Officer. With over three decades of experience in the healthcare industry, Glenn has successfully led strategies for both private and public financings and has played an integral role in building infrastructures that support company growth and pipeline expansion. We look forward to his many contributions to Eccogene. Read more: https://lnkd.in/eWFRiZ6y

Microsoft Exchange Online

Office 365 Mail

GoDaddy DNS

Alibaba

Clinical Operations Head and Medical Director

Jianfeng Xu

Associate Director Clinical Operations

Laurie Butcher

Business Management

President

Michael Wiley

Head of CMC

Co-founder and CEO

Co-Founder and CSO

Companies With More Than $10M in Revenue (Top 10K)

Asia-Pacific (APAC) Health Care Companies with Early Stage Venture Funding

China Early Stage Companies With Fewer Than 50 Employees

Asia-Pacific (APAC) Startups (Top 10K)

Eccogene is a clinical stage biopharmaceutical company that provides therapeutic solutions to address unmet medical needs. They offer services in the discovery and development of translational medicine in metabolic and immune-related diseases.

New Alliance Capital

Shanghai Zhangjiang Haocheng Venture Capital

Series B - Eccogene

Sinopharm Capital

Series A - Eccogene

Shanghai

China

Asia

AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug

AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial

Eccogene gets $60M from AstraZeneca; Evotec also records milestone with BMS

AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH candidates

China Digest: Eccogene, UDS, Emposat snap funding

Eccogene Raises CNY 180M in Series B Equity Financing

Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech

Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl …

United States

North America

Hong Kong

Poland

Europe

Indonesia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 2:56 AM	1179a39a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 2:56 AM	d41759c8
crunchbase trigger	general	Nov 12, 2024 2:56 AM	af075b00
crunchbase profile	general	Nov 12, 2024 10:58 AM	0848ae57
li profile	general	Nov 12, 2024 2:56 AM	2ef4a393
translate crunchbase fundingrounds	general	Nov 12, 2024 11:36 AM	db84f397
peers	general	Nov 12, 2024 2:56 AM	30c810a5
news basic	general	Nov 12, 2024 2:56 AM	f8973fe3
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ECCO

COM:ECCOGENE

Eccogene